Best of the Week
Most Popular
1. TESLA! Cathy Wood ARK Funds Bubble BURSTS! - 12th May 21
2.Stock Market Entering Early Summer Correction Trend Forecast - 10th May 21
3.GOLD GDX, HUI Stocks - Will Paradise Turn into a Dystopia? - 11th May 21
4.Crypto Bubble Bursts! Nicehash Suspends Coinbase Withdrawals, Bitcoin, Ethereum Bear Market Begins - 16th May 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.Cathy Wood Ark Invest Funds Bubble BURSTS! ARKK, ARKG, Tesla Entering Severe Bear Market - 13th May 21
7.Stock Market - Should You Be In Cash Right Now? - 17th May 21
8.Gold to Benefit from Mounting US Debt Pile - 14th May 21
9.Coronavius Covid-19 in Italy in August 2019! - 13th May 21
10.How to Invest in HIGH RISK Tech Stocks for 2021 and Beyond - Part 2 of 2 - 18th May 21
Last 7 days
RAMPANT MONEY PRINTING INFLATION BIG PICTURE! - 16th Jun 21
The Federal Reserve and Inflation - 16th Jun 21
Inflation Soars 5%! Will Gold Skyrocket? - 16th Jun 21
Stock Market Sentiment Speaks: Inflation Is For Fools - 16th Jun 21
Four News Events That Could Drive Gold Bullion Demand - 16th Jun 21
5 ways that crypto is changing the face of online casinos - 16th Jun 21
Transitory Inflation Debate - 15th Jun 21
USDX: The Cleanest Shirt Among the Dirty Laundry - 15th Jun 21
Inflation and Stock Market SPX Record Highs. PPI, FOMC Meeting in Focus - 15th Jun 21
Stock Market SPX 4310 Right Around the Corner! - 15th Jun 21
AI Stocks Strength vs Weakness - Why Selling Google or Facebook is a Big Mistake! - 14th Jun 21
The Bitcoin Crime Wave Hits - 14th Jun 21
Gold Time for Consolidation and Lower Volatility - 14th Jun 21
More Banks & Investors Are NOT Believing Fed Propaganda - 14th Jun 21
Market Inflation Bets – Squaring or Not - 14th Jun 21
Is Gold Really an Inflation Hedge? - 14th Jun 21
The FED Holds the Market. How Long Will It Last? - 14th Jun 21
Coinbase vs Binance for Bitcoin, Ethereum Crypto Trading & Investing During Bear Market 2021 - 11th Jun 21
Gold Price $4000 – Insurance, A Hedge, An Investment - 11th Jun 21
What Drives Gold Prices? (Don't Say "the Fed!") - 11th Jun 21
Why You Need to Buy and Hold Gold Now - 11th Jun 21
Big Pharma Is Back! Biotech Skyrockets On Biogen’s New Alzheimer Drug Approval - 11th Jun 21
Top 5 AI Tech Stocks Trend Analysis, Buying Levels, Ratings and Valuations - 10th Jun 21
Gold’s Inflation Utility - 10th Jun 21
The Fuel Of The Future That’s 9 Times More Efficient Than Lithium - 10th Jun 21
Challenges facing the law industry in 2021 - 10th Jun 21
SELL USDT Tether Before Ponzi Scheme Implodes Triggering 90% Bitcoin CRASH in Cryptos Lehman Bros - 9th Jun 21
Stock Market Sentiment Speaks: Prepare For Volatility - 9th Jun 21
Gold Mining Stocks: Which Door Will Investors Choose? - 9th Jun 21
Fed ‘Taper’ Talk Is Back: Will a Tantrum Follow? - 9th Jun 21
Scientists Discover New Renewable Fuel 3 Times More Powerful Than Gasoline - 9th Jun 21
How do I Choose an Online Trading Broker? - 9th Jun 21
Fed’s Tools are Broken - 8th Jun 21
Stock Market Approaching an Intermediate peak! - 8th Jun 21
Could This Household Chemical Become The Superfuel Of The Future? - 8th Jun 21
The Return of Inflation. Can Gold Withstand the Dark Side? - 7th Jun 21
Why "Trouble is Brewing" for the U.S. Housing Market - 7th Jun 21
Stock Market Volatility Crash Course (VIX vs VVIX) – Learn How to Profit From Volatility - 7th Jun 21
Computer Vision Is Like Investing in the Internet in the ‘90s - 7th Jun 21
MAPLINS - Sheffield Down Memory Lane, Before the Shop Closed its Doors for the Last Time - 7th Jun 21
Wire Brush vs Block Paving Driveway Weeds - How Much Work, Nest Way to Kill Weeds? - 7th Jun 21
When Markets Get Scared and Reverse - 7th Jun 21
Is A New Superfuel About To Take Over Energy Markets? - 7th Jun 21
Why Tether USDT, Stable Scam Coins Could COLLAPSE the Crypto Markets - Black Swan 2021 - 6th Jun 21
Stock Market: 4 Tips for Investing in Gold - 6th Jun 21
Apple (AAPL) Summer Correction Stock Trend Analysis - 5th Jun 21
Stock Market Sentiment Speaks: I 'Believe' We Rally Into A June Swoon - 5th Jun 21
Stock Market Russell 2000 After Reaching A Trend Channel High Flags Out - 5th Jun 21
Money Is Cheap, Own Gold - 5th Jun 21
Bitcoin and Ravencoin Cryptos CRASH Bear Market Buying Levels Price Targets - 4th Jun 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

3 World-Shaking Trends Investors Need To Watch This Year

Companies / BioTech May 21, 2021 - 04:03 PM GMT

By: FinancialMorningPost

Companies

Never before have this many life-changing trends converged at the same time to give investors a cornucopia of rewarding opportunities. 

In the energy tech space, we’re staring in the face of a multi-trillion-dollar transition. It’s a high-speed train in some respects, with investors misunderstanding the timing. But when it’s done right, these are longer-term smart plays of the kind that will surely mint the next millionaires--or billionaires.

What the future holds for battery tech is where some of the biggest money is heading in this transition landscape. 

In the healthcare sector, we’re in the middle of a wellness revolution that first saw a cannabis boom that rewarded many investors nicely, with round two likely in the making, but now, something even bigger might be afoot. 

Psychedelics are being prepped now--even from the FDA’s perspective--as an answer to an out-of-control global problem with depression.  Heading towards $4.5 trillion, the global wellness sector is exploding, and the answers to many of our problems is the holy grail. 


In the cyber security segment, the recent ransomware attack on America's largest natural gas pipeline brought our abysmal security into full view--if it wasn’t already. Add to that the new, pandemic-driven trend for remote work and online schooling has rendered the ‘cloud’ a very precarious place to be, indeed. The future of cyber security is in the cloud, and investors should be looking for the next pioneer. 

Here are 3 stocks that are aiming to reshape our future in a very big way: 

#1 Quantumscape (NYSE:QS)

Quantumscape and its “Jesus battery” is one of the most exciting stocks on the speculative, futuristic energy transition scene. It’s backed by Bill Gates and Microsoft (NASDAQ:MSFt), not to mention Volkswagen (OTCMKTS:VWAGY). And it fully intends to radicalize EV battery technology. 

What’s not to love?

But timing here is important. Investors piled into this far too soon, pushing it far too high, too fast. Now, it’s settled back down to a reality that reflects the timing. 

There will be a second-coming, though, and we think this is one of the better longer-term bets on our multi-trillion-dollar energy transition. 

Why? Because this solid-state battery offering could disrupt everything …

Solid-state battery cells are the EV game-changer, offering high performance and safety at a low cost. 

QuantumScape’s prototype batteries use a solid ceramic electrolyte, which the company sees as a safer alternative to liquid electrolytes. They claim that the battery can hit an 80% charge in just 15 minutes. That removes one of the biggest hurdles to widespread, mainstream adoption of EVs. Currently, the best lithium-ion batteries pack about 250Wh/kg, while solid-state batteries already exceed 400Wh/kg. 

Eventually, this company stands to be one of the biggest winners of the energy transition, but it’s an investment that will take some patience for that juicy end reward. 



#2 HAVN LIFE
(CSE: HAVN; OTC: HAVLF)

Look no further than this for the next entry into servicing this megatrend in the $52-billion pain management market, the $14-billion antidepressant market and a soon-to-be $4.5 trillion global wellness space. 

This is where psychedelics are now losing their stigma and could soon be in the mainstream. This could get even bigger than cannabis because it could end up being a solution to the most tragic illness of our time--depression. 
Psychedelics are emerging as the potential key to pain management and multiple forms of depression.  And it’s all about science, with HAVN Life gunning for pole position in the supply chain. 

HAVN Life is an extraction innovator that is setting itself up to be the supplier to the growing number of labs and clinical providers hedging their bets on this healthcare breakthrough. Even the FDA is calling the key compound that for cases of severe depression.

The key to it all is a compound called psilocybin, the active ingredient in magic mushrooms.

We are optimistic about HAVN Life’s strong emergence in this segment because some of its management played a huge role in the first cannabis boom--another major element of a mega wellness revolution that is unfolding. 

The Chaiman of HAVN Life (CSE: HAVN; OTC: HAVLF) Vic Neufeld and CSO Gary Leong were the founders of Aphria (NYSE:APHA), which netted the earliest investors gains of over 2,300%.

They’ve got two revenue verticals: Havn Labs and Havn Retail. 

HAVN Labs is looking to meet soaring demand for psilocybin for clinical research, and it’s spending C$800,000 on a new state-of-the-art mycology laboratory in Vancouver. That lab is scheduled to launch this year and stands to become the premier extraction facility for naturally-derived clinical compounds. 

HAVN retail is hedging on surging demand for supplements, with the total Canadian vitamins and minerals market valued at $521 million, and the U.S. market valued at over $7.4 billion. In this huge market, mushrooms were the second fastest growing natural health supplement and are underserved in the market. HAVN Life intends to change that. 
This stock has already been added to the Horizons Psychedelic Stock Index ETF (PSYK), where investors gain exposure to a basket of 17 publicly traded companies focused on using psychedelics to treat a wide range of mental health issues.  

The news flow is expected to be fast-paced, especially amid a new decriminalization drive that if successful, could make psychedelics a $100-billion market segment before we know it. 

And we’ll be closely watching the next big potential boost for this company: Results from preclinical trials to investigate the effects of psilocybin on the immune system--a potentially ground-breaking study that could lead to the development of new medicines.

#3 CrowdStrike (NASDAQ:CRWD)

The cyber security segment is over-ripe for a major disruption, and CrowdStike seems ready to do just that, if it hasn’t already gotten a great foothold on the cyber security of the future. 

Everything’s on the cloud these days. Now, it’s time for cyber security--always a few steps behind the hackers--to catch up. 

This company is arguably the pioneer of the security cloud. There is quite a lot of new tech here that sets CrowdStrike apart from others in the cyber security field, but the growth potential here is what investors should be looking at. 

CrowdStrike’s platform uses crowdsourced data for analysis and continual improvements. 

And while it’s only got 10,000 customers right now, it’s the growth trajectory that has radar pinging. Not to mention spectacular revenue numbers: CRWD grew revenue by over 81% for fiscal 2021. 

On this one, it’s already exploded, so wait for the dip to get in. That dip isn’t going to come just yet because CRWD just announced some fairly big news: A new deal with Google Cloud.

Already partners, CrowdStrike and Google Cloud announced on May 10th that they will be extending their partnership via new product integrations that will allow customers to share telemetry and data between the two platforms.  



By. Davao Vance



**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Forward-Looking Statements

This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include that the global wellness market will continue to increase and that demand for mushroom based supplements and nutraceuticals will grow; that the market for psychedelic mushrooms will continue to increase for research purposes focused on alternative mental health treatments; that psychedelics will gain regulatory, medical, commercial and social acceptance as a potential treatment for various mental and other illnesses; that HAVN can be a supplier of functional and psychedelic mushroom products; that HAVN can be a leader in scientific research and achieve a new standard in naturally derived psilocybin; that HAVN can successfully build out supply agreements with researchers and obtain supply agreements to create commercialized products; that HAVN will develop fungi-based nutraceutical products for the wellness market that will achieve Health Canada approval and be sold on e-commerce sites and by retailers; that HAVN can produce products using specialized extracts which have a greater therapeutic effect for patients; the projected timing of product launches and availability through retailers; that psychedelic mushrooms will be decriminalized and gain acceptance as a viable medical treatment for mental illness; that HAVN will develop a state-of-the-art research lab and become a supplier for the psychedelic and functional mushroom markets; and that HAVN can carry out its business plans. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information.  Risks that could change or prevent these statements from coming to fruition include that the global wellness market may not increase as anticipated and that demand for supplements, and in particular mushroom based supplements and nutraceutical based products may not increase; that the market for psychedelic mushrooms does not increase; that psychedelic mushroom based treatments are found to be dangerous, ineffective or have unwanted side effects; that psychedelics will fail to gain regulatory, medical, commercial and social acceptance as a potential treatment for various mental and other illnesses; that HAVN may be unable to develop its business as a supplier of functional and psychedelic mushroom products; that HAVN may fail to become a leader in scientific research or achieve a new standard in naturally derived psilocybin; that HAVN may fail to achieve supply agreements with researches or obtain supply agreements to create any additional commercialized products; even if they do successfully produce products, competitors may offer better and cheaper products; that HAVN’s products may prove not effective; and that its intellectual property may be challenged as infringing on others’ IP. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

DISCLAIMERS

This communication is for entertainment purposes only. Never invest purely based on our communication. FinancialMorningPost.com and its owners and affiliates (“FinancialMorningPost.com”) are being paid ninety thousand USD for this article as part of a larger marketing campaign for CSE:HAVN. The information in this report and on our website has not been independently verified and is not guaranteed to be correct.

SHARE OWNERSHIP. The owner and affiliates of FinancialMorningPost.com own shares of HAVN and therefore have an additional incentive to see the featured company’s stock perform well. FinancialMorningPost.com is therefore conflicted and is not purporting to present an independent report. The owner and affiliates of FinancialMorningPost.com will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of FinancialMorningPost.com will be buying and selling shares of this issuer for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. 

NOT AN INVESTMENT ADVISOR. FinancialMorningPost.com is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation, nor are any of its writers or owners.

ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

RISK OF INVESTING. Investing is inherently risky. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any stock acquisition will or is likely to achieve profits. 


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in